Abstract

Precision dosing in oncology represents a transformative approach in cancer treatment, tailored to maximize therapeutic efficacy while minimizing adverse effects. This approach is particularly relevant in the context of nextgeneration therapeutics, including targeted therapies and immunotherapies, which exhibit complex pharmacokinetic (PK) profiles. Understanding the intricate dynamics of drug absorption, distribution, metabolism, and excretion is critical for optimizing dosing regimens. This review explores the pharmacokinetics of emerging oncological agents, emphasizing the role of PK modeling and simulations in predicting optimal dosing strategies. The integration of patientspecific factors such as genetic variations, organ function, and drug-drug interactions is discussed, highlighting its impact on personalized treatment plans. Advances in precision dosing methodologies, including the use of biomarkers and real-time therapeutic drug monitoring, are evaluated for their potential to enhance clinical outcomes. The challenges and future directions in implementing precision dosing in clinical practice are also addressed, with a focus on improving therapeutic indices and reducing toxicity in cancer patients